Figure Legends
Fig. 1. Study population with comparison of skin prick test and allergen-specific IgE measurement results between clinically confirmed non-allergic controls and peanut allergic patients. (A) Blinded MONA study serum samples (n=112) from the Toronto site with available clinical status were transferred to the University of Bern. Serum samples for which BAT data was recorded in MONAS (n=96) were included in the clinical performance analysis of the Hoxb8 MAT and in direct comparison to BAT. Amongst those SPT information for 47 samples and sIgE measurements for 67 samples has been available. (B) Wheal size measurement results from skin prick test compared between non-allergic controls (NA; blue) and peanut allergic patients (PA; red). (C) Comparison of allergen-specific IgE measurements by ImmunoCAP for peanut extract, Ara h1, Ara h2, Ara h3, Ara h8 and Ara h9 between non-allergic controls (NA; blue) and peanut allergic patients (PA; red). Data are shown as individual data points and means ± SEMs. *P < 0.05, ****P < 0.001, ns = not significant.
Fig. 2. Performance analysis of Hoxb8 MAT and BAT to differentiate between clinically confirmed non-allergic controls and peanut allergic patients. Passively sensitized Hoxb8 MCs (A and B) or whole blood (C and D) were stimulated with peanut allergen extract at various doses (0-1000 ng/ml). Comparison of activated Hoxb8 MCs or blood basophils in the non-allergic (NA) and peanut allergic (PA) group on a population basis is shown (A and C). Dose-response curves of activated Hoxb8 MCs and blood basophils for individual patient samples are represented in two separate subpanels (B and D). Non-allergic controls are depicted in blue, while peanut allergic patients are represented in red. (E and F) ROC curve analyses for Hoxb8 MAT and BAT results across different allergen concentrations (color coded) are depicted and AUROC values are indicated. Data are shown as individual data points and means ± SEMs. *P < 0.05, ****P < 0.001.
Fig. 3. Correlation analysis between skin prick test or allergen-specific IgE measurements and maximal activation signal in the Hoxb8 MAT. Wheal size results from skin prick test (A) or allergen specific IgE measurement for peanut extract (B), Ara h1 (C) and Ara h2 (D) from non-allergic controls (red dots) and allergic patients (blue dots) were plotted against the maximal activation signal from the Hoxb8 MAT and a linear correlation analysis (red line) was performed. The correlation coefficient (r) as well as the significance of the correlation (p) are indicated for each subpanel.
Fig. 4. Analysis of seven BAT non-responder samples with the Hoxb8 MAT. Seven sera from previously identified BAT non-responders (NR1-7) were measured on passively sensitized Hoxb8 MCs. The clinically confirmed allergy status of the individual patient samples is color coded (peanut allergic, PA: red; non-allergic, NA: blue; no Information, NI: orange).
Fig. 5. Direct comparison of performance analyses between different diagnostic tests. Direct ROC curve analysis for SPT and sIgE against peanut extract compared with ROC curve analysis of logistic regression models with Hoxb8 MAT and BAT results including all peanut allergen concentrations are depicted (color coded) and AUROC values are indicated.